PRENOR PRENOR TEMFIN ORGESIC ZONOR ZONOR DORFENE BUPREGESIC TEMGESIC BUEPRON GESIC BUNORFIN BUNORFIN DORGESIC GESNOR BRUCIPIN BRUCIPIN RUKGASEE TEMGESIC SUBLINGUAL OPINOR PROZEM BUPREDAN BEPNOR BENORINE ISBUP ZUROFIN BUPRENWAN BUPRI-U MEDIBUNOR TEMGO NORPHINE NORPHINE OPRONIEX SEGESIC SEMOXIN BUPER MOMMI

Dose: 0.3 to 0.6 mg
Single Dose: 0.45 (0.45)
Frequency: 8 hourly
Route: IV,IM
Instructions:

Dose: 3 to 9 ug/kg
Single Dose: 6 (6)
Frequency: 8 hourly
Route: Intramuscular
Instructions:

Dose: 3 to 9 ug/kg
Single Dose: 6 (6)
Frequency: 8 hourly
Route: Intra Muscular
Instructions: -

. It is of Synthetic origin and belongs to Opiate. It belongs to OPIATE agonist pharmacological group on the basis of mechanism of action and also classified in Analgesics and Anti-inflammatory Agents and Analgesic-Narcotic pharmacological group.The Molecular Weight of Buprenorphine (HCl) is 504.00. Its pKa is 8.42, 9.92.

Buprenorphine (HCl) is contraindicated in conditions like Phaeochromocytoma,Respiratory disease,Paralytic ileus,Head injury,Atrophic oral candidiasis associated with dentures.

The severe or irreversible adverse effects of Buprenorphine (HCl), which give rise to further complications include Hallucinations.Buprenorphine (HCl) produces potentially life-threatening effects which include Respiratory depression. which are responsible for the discontinuation of Buprenorphine (HCl) therapy.The symptomatic adverse reactions produced by Buprenorphine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vertigo, Headache, Nausea, Vomiting, Constipation, Sweating.

Buprenorphine (HCl) is primarily indicated in conditions like Adjunct in the treatment of opiod dependence, Adjunct to prevent relapse, Advanced breast cancer in postmenopausal women, All forms of epilepsy, Cocaine withdrawal, Moderate to severe acute pain, Moderate to severe chronic pain, Moderate to severe pain, Myoclonus, Opioid agonist dependence, Post operative analgesia.

Buprenorphine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAlfentanil (HCl)Naloxone (HCl)VORICONAZOLEVoriconazole may increase the serum concentration of buprenorphine by decreasing its metabolismMonitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Pregnant Mothers, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store Below 40°C. Do not Freeze. Protect from Sunlight.

Buprenorphine should be used with caution and in low doses in patients with lungs, liver or kidney impairment, central nervous system (CNS) depression or patients undergoing biliary tract surgery. Patients should observe caution while driving or performing tasks requiring alertness, because it may cause drowsiness.